Compositions for and method of treating acid-base disorders
AssigneeRenosis, Inc.
InventorsGerrit Klaerner, Jerry M. Buysse, Jun Shao, Dawn Parsell Otto
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.
Claims27
1-65. (canceled)
A method of treating a patient with a lithiasis disorder, wherein the method comprises oral administration of a nonabsorbable pharmaceutical composition comprising a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 1:
- wherein R1, R2 and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl provided, however, at least one of R1, R2 and R3 is other than hydrogen, the crosslinked amine polymer binds a molar ratio of chloride ions to interfering ions of at least 0.35:1, respectively, in an interfering ion buffer at 37° C. wherein the interfering ions are phosphate ions and the interfering ion buffer is a buffered solution at pH 5.5 of 36 mM chloride and 20 mM phosphate or (ii) the interfering ions are phosphate, citrate and taurocholate ions (combined amount) and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride, 7 mM phosphate, 1.5 mM citrate, and 5 mM taurocholate.
A method of treating a patient with a lithiasis disorder, wherein the patient has a serum bicarbonate value of at least 22 mEq/l prior to the treatment, wherein the method comprises oral administration to the patient in need thereof of a proton-binding crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2 or a salt thereof
- wherein
- m and n are independently non-negative integers;
- R10, R20, R30, and R40 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl;
- X1 is
- X2 is hydrocarbyl or substituted hydrocarbyl;
- each X11 is independently hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxy, or amino;
- z is a non-negative number,
- the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of 2 or less;
- and
- the crosslinked amine polymer binds a molar ratio of chloride ions to interfering ions of at least 0.35:1, respectively, in an interfering ion buffer at 37° C. wherein the interfering ions are phosphate ions and the interfering ion buffer is a buffered solution at pH 5.5 of 36 mM chloride and 20 mM phosphate.
Dependencies are inferred from the claim text.